Guardant Health (GH) Fundamental Analysis: Revenue, Earnings & Valuation

2.11 / 10

Underperform

Fundamental analysis rates Guardant Health at 2.11/10, classifying it as Underperform. Profit‑MV and Cash‑MV are modestly positive, while Asset‑MV and Revenue‑MV are negative. Margins are weak, and key ratios such as Gross Profit and Cost‑of‑Sales show unfavorable trends.

Analysis Checks(6/10)

Revenue-MV

Value-1.47

Score1/3

Weight36.70%

1M Return5.44%

Inventory turnover ratio

Value4.45

Score2/3

Weight-2.70%

1M Return-0.56%

Gross profit margin (%)

Value64.46

Score0/3

Weight-21.35%

1M Return-5.42%

Profit-MV

Value0.68

Score2/3

Weight41.90%

1M Return6.36%

Income tax / Total profit (%)

Value0.30

Score2/3

Weight5.26%

1M Return0.98%

Current assets turnover ratio

Value0.78

Score1/3

Weight-0.91%

1M Return-0.17%

Fixed assets turnover ratio

Value3.36

Score2/3

Weight0.05%

1M Return0.01%

Cost of sales ratio (%)

Value35.54

Score2/3

Weight-17.17%

1M Return-3.62%

Asset-MV

Value-0.55

Score0/3

Weight17.19%

1M Return2.73%

Cash-MV

Value0.03

Score2/3

Weight41.05%

1M Return6.19%

Is GH fundamentally strong?

GH scores 2.11/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -42.39% net margin, -27.28 P/E ratio, -114.36 P/B ratio, and 6.74% earnings growth, these metrics solidify its Underperform investment rating.